BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 2859332)

  • 1. Participation of class II alloantigens in in vivo regulation of K/D region disparate thyroid graft rejection in mice.
    Isakov N; Bach FH
    J Immunol; 1985 Jun; 134(6):3580-5. PubMed ID: 2859332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High frequency of splenic anti-class I cytotoxic T lymphocyte precursors correlates with in vivo rejection of K/D region disparate thyroid and islet grafts in mice.
    Isakov N; Bach FH
    J Immunol; 1984 Jan; 132(1):50-6. PubMed ID: 6418804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor allograft rejection is mainly mediated by CD8+ cytotoxic T lymphocytes stimulated with class I alloantigens in cooperation with CD4+ helper T cells recognizing class II alloantigens.
    Tomita Y; Mayumi H; Eto M; Nomoto K
    J Immunol; 1990 Mar; 144(6):2425-35. PubMed ID: 1968930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerance induction of allo-class II H-2 antigen-reactive L3T4+ helper T cells and prolonged survival of the corresponding class II H-2-disparate skin graft.
    Hori S; Sato S; Kitagawa S; Azuma T; Kokudo S; Hamaoka T; Fujiwara H
    J Immunol; 1989 Sep; 143(5):1447-52. PubMed ID: 2527264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigen presentation by Langerhans cells in vivo: donor-derived Ia+ Langerhans cells are required for induction of delayed-type hypersensitivity but not for cytotoxic T lymphocyte responses to alloantigens.
    Peeler JS; Niederkorn JY
    J Immunol; 1986 Jun; 136(12):4362-71. PubMed ID: 3519767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic and stimulatory cell type requirements for inducing class I major histocompatibility complex alloantigen-specific in vivo cytotoxic T cell immunity.
    Mizoguchi K; Nakashima I; Isobe K; Ando K; Nagase F; Kato N; Kawashima K; Shimokata K; Hasegawa Y
    Eur J Immunol; 1985 May; 15(5):487-94. PubMed ID: 3873341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rejection of skin allografts by CD4+ T cells is antigen-specific and requires expression of target alloantigen on Ia- epidermal cells.
    Rosenberg AS; Katz SI; Singer A
    J Immunol; 1989 Oct; 143(8):2452-6. PubMed ID: 2477443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune mechanisms in organ allograft rejection. III. Cellular and humoral immunity in rejection of organ allografts transplanted across MHC subregion disparity RT1.B (RT1.D).
    Lowry RP; Gurley KE
    Transplantation; 1983 Oct; 36(4):405-11. PubMed ID: 6353708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo priming of mouse CTL precursors directed to product of a newly defined minor H-42 locus is under a novel control of class II MHC gene.
    Ishikawa H; Suzuki H; Hino T; Kubota E; Saito K
    J Immunol; 1985 Dec; 135(6):3681-5. PubMed ID: 3934264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific tolerance induction of allo-K(b)-skin grafts by FK506 in the CD8-depleted H-2(k) recipients required low amounts of K(b)-antigen.
    Chen BG; Liu Z; Wu Y
    Transpl Immunol; 2005 Oct; 15(1):9-16. PubMed ID: 16223668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic control of variability in responses to class-I-antigen-disparate thyroid grafts.
    Isakov N; Bach FH
    Transplantation; 1985 Mar; 39(3):303-9. PubMed ID: 3919481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Murine orthotopic corneal transplantation in high-risk eyes. Rejection is dictated primarily by weak rather than strong alloantigens.
    Sano Y; Ksander BR; Streilein JW
    Invest Ophthalmol Vis Sci; 1997 May; 38(6):1130-8. PubMed ID: 9152232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transplantation of cultured thymic fragments. VI. H-2 recombinant donors.
    Jenski LJ; Hong R
    J Immunol; 1985 Aug; 135(2):947-53. PubMed ID: 2409162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific prolongation of MHC class II disparate skin allografts by in vivo administration of anti-IFN-gamma monoclonal antibody.
    Rosenberg AS; Finbloom DS; Maniero TG; Van der Meide PH; Singer A
    J Immunol; 1990 Jun; 144(12):4648-50. PubMed ID: 2112572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of the mutated H-2Kbm1 antigen(s). Test of thyroid graft rejection between B6.C-H-2bm1 and C57BL/6 mice following reciprocal immunization with normal versus malignant cells.
    Isakov N; Segal S
    Immunobiology; 1983 Dec; 165(5):485-99. PubMed ID: 6363278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of transplantation immunity in vivo by monoclonal antibodies recognizing host class II restriction elements. II. Effects of anti-Ia immunotherapy on host T cell responses to graft alloantigens.
    Williams IR; Perry LL
    J Immunol; 1985 May; 134(5):2942-7. PubMed ID: 3156920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrathymic alloantigen-mediated, tolerant, completely major histocompatibility complex-mismatched mouse hearts are specifically rejected by adoptively transferred anti-class I L(d+)-specific 2C cells.
    Otomo N; Motoyama K; Yu S; Shimizu Y; Margenthaler J; Tu F; Flye MW
    Surgery; 2000 Aug; 128(2):206-12. PubMed ID: 10922993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of F1 cytotoxic potentials by graft-vs-host reaction. Cooperative non-H-2- and H-2D region-gene control of F1 natural resistance to graft-vs-host reaction-associated immunosuppression.
    Ishikawa H; Saito K; Kubota E
    J Immunol; 1989 Mar; 142(5):1495-9. PubMed ID: 2918225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptively transferred CD4+ lymphocytes from CD8 -/- mice are sufficient to mediate the rejection of MHC class II or class I disparate skin grafts.
    Dalloul AH; Chmouzis E; Ngo K; Fung-Leung WP
    J Immunol; 1996 Jun; 156(11):4114-9. PubMed ID: 8666777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A synthetic CD4-CDR3 peptide analog enhances skin allograft survival across a MHC class II barrier.
    Koch U; Choksi S; Marcucci L; Korngold R
    J Immunol; 1998 Jul; 161(1):421-9. PubMed ID: 9647252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.